The Science of
GLOW Peptide
A synergistic triple-peptide formulation — BPC-157, TB-500, and GHK-Cu — engineered to address tissue repair, collagen synthesis, angiogenesis, and cellular regeneration through complementary, non-overlapping biological pathways.
What is the GLOW Blend?
A precisely formulated triple-peptide stack combining three extensively studied bioactive compounds, each operating through distinct molecular pathways to create a comprehensive regenerative effect.
The GLOW blend combines BPC-157, TB-500, and GHK-Cu into a single formulation, leveraging the complementary mechanisms of three well-documented peptides. Each peptide has a distinct molecular target, yet their effects converge on the same biological outcome: optimized tissue repair, reduced inflammation, and accelerated cellular regeneration.
The rationale for combining these peptides lies in the hypothesis that parallel modulation of nitric oxide signaling, cytoskeletal dynamics, extracellular matrix remodeling, and oxidative stress responses may produce additive or synergistic effects in controlled research models.
BPC-157 provides structural reattachment and vascular support via NO pathway modulation. TB-500 coordinates cellular migration and prevents fibrosis through actin sequestration. GHK-Cu delivers antioxidant protection and gene-level regulation of tissue remodeling via TGFβ1 pathways.
Together, these peptides address complementary aspects of the entire healing cascade — from the initial injury response through final tissue remodeling — making this blend particularly relevant for complex musculoskeletal injuries, post-surgical recovery, and systemic anti-aging applications.
- GHK-Cu at the highest dose (5 parts) anchors collagen synthesis and gene regulation
- TB-500 and BPC-157 at equal lower doses (1 part each) handle vascular and structural repair
- Typical full dose: 1.7 mg GHK-Cu · 0.33 mg TB-500 · 0.33 mg BPC-157 per injection
The Three Pillars of GLOW
Each peptide in the GLOW blend has been independently studied for decades. Understanding their individual mechanisms reveals why their combination is so potent.
Scroll or use tabs above to jump to each peptide ↓
BPC-157 modulates the nitric oxide (NO) synthase pathway via the Akt-eNOS axis, promoting vascular endothelial growth factor (VEGF) signaling. It activates FAK-paxillin and ERK1/2 signaling cascades, facilitating fibroblast migration and angiogenesis. Effects appear to be mediated through changes in gene expression rather than direct receptor agonism.
- Accelerated tendon outgrowth and fibroblast migration in Achilles tendon models (J. Applied Physiology, 2011)
- Improved outcomes in muscle, tendon, ligament, and bone models — 35 preclinical studies reviewed (PMC, 2025)
- 7 of 12 knee pain patients reported relief >6 months post-injection (Lee & Padgett, 2021)
- Pleiotropic neuroprotective effects via neurotransmitter modulation (Pharmaceuticals, 2024)
- No lethal/toxic dose observed in preclinical safety studies
- Tendon rupture and ligament tear healing
- Muscle injury and bone fracture repair
- Gastrointestinal mucosal protection
- Neurological injury recovery (TBI, stroke models)
- Interstitial cystitis (pilot study, 2024)
- No adverse effects reported across preclinical studies
- IV infusions up to 20mg well-tolerated in healthy adults (Lee & Burgess, 2025)
- VEGFR2 upregulation: theoretical oncological risk in patients with existing malignancy
- Human safety data remains limited — clinical trials pending
- FDA flagged for compounding in 2023
TB-500 functions as the major G-actin sequestering molecule in cells, regulating actin polymerization which drives cellular migration and tissue repair. It activates PI3K/Akt and ILK pathways, promotes VEGF-mediated angiogenesis, and polarizes macrophages toward the regenerative M2 phenotype — reducing fibrotic remodeling.
- Increased re-epithelialization by 42% at day 4 and 61% at day 7 vs saline controls (NIH, PubMed 10469335)
- First molecule shown to initiate simultaneous myocardial & vascular regeneration in vivo (PubMed 20536454)
- Reactivates dormant cardiac progenitor (epicardial) cells independent of ischemic injury
- Reduced neuronal loss and glial scarring in spinal cord injury models
- Phase II dermal trials: safe, well-tolerated, accelerated pressure/stasis ulcer healing
- Dermal wound healing (diabetic ulcers, pressure sores)
- Cardiac repair post-myocardial infarction
- Corneal wound healing and re-epithelialization
- Musculoskeletal recovery (muscle, tendon)
- Neurological injury recovery (spinal cord, stroke)
- TB-500: actin sequestration, cardiac/muscle profile, anti-fibrotic
- BPC-157: NO synthesis, tendon/GI profile, stronger angiogenic signaling
- Both are pro-angiogenic via distinct pathways
- Combined study provides broader repair biology coverage
- Complementary rather than redundant mechanisms
GHK-Cu is released from the parent protein SPARC during extracellular matrix degradation, directly signaling tissue damage. It modulates TGFβ1 pathways and metalloproteinase (MMP/TIMP) activity, simultaneously stimulating collagen synthesis while breaking down damaged collagen. Via the Broad Institute Connectivity Map, GHK has been shown to upregulate 59% and suppress 41% of modulated genes — essentially resetting DNA to a healthier state.
- Collagen increase in 70% of subjects — outperforming vitamin C (50%) and retinoic acid (40%) (Abdulghani et al., 1999)
- 12-week facial cream trial: improved skin laxity, density, wrinkle depth in 71 women (Leyden et al.)
- GHK-Cu + HA combination: 25.4× increase in collagen IV synthesis in cell tests (PubMed 37062921)
- Reversed COPD-associated gene expression patterns in lung fibroblasts
- GHK-Cu significantly increases MMP1/MMP2 while simultaneously boosting TIMP1 (Badenhorst et al., 2016)
- Skin regeneration, anti-aging, photoaging reversal
- Wound healing (skin, GI tract, lung, bone)
- Collagen/elastin synthesis and ECM remodeling
- Hair follicle stimulation (particularly with microneedling)
- Potential COPD and lung tissue repair
- Naturally occurring — declines significantly with age
- Acts on 4,000+ human genes (Broad Institute data)
- Modulates both production and breakdown of structural proteins (dual regulation)
- Copper cofactor essential for lysyl oxidase activity in collagen cross-linking
- Penetrates stratum corneum — topical application viable
The Synergy of Three
While each peptide targets distinct molecular pathways, their combined biological actions converge on the same therapeutic outcomes — creating effects that may exceed the sum of their parts.
Peer-Reviewed Research Data
The following studies represent key findings from the scientific literature on GLOW's individual component peptides. All findings are from published, peer-reviewed sources.
Where GLOW is Applied
The broad-spectrum regenerative profile of the GLOW blend makes it relevant across multiple therapeutic domains, each leveraging different aspects of the peptide synergy.
Research Protocol Reference
Standard research-grade protocols as documented in the literature. This information is provided for educational and research reference purposes only.
| Parameter | Standard Protocol |
|---|---|
| Blend ratio | 5:1:1 (GHK-Cu : TB-500 : BPC-157) |
| Total daily dose | 2,330 mcg (2.33 mg) blend |
| GHK-Cu per dose | ~1.70 mg (71.4%) |
| TB-500 per dose | ~0.33 mg (14.3%) |
| BPC-157 per dose | ~0.33 mg (14.3%) |
| Route | Subcutaneous injection |
| Frequency | Once daily (consistent time) |
| Cycle length | 4 weeks continuous |
| Rest period | 2–4 weeks between cycles |
| Reconstitution | 3.0 mL bacteriostatic water per 70 mg vial |
| Injection sites | Abdomen / buttocks — rotate |
GLOW is not FDA-approved for human use. BPC-157 and TB-500 have been flagged by the FDA for compounding concerns. All protocols listed here are derived from research literature and are for informational and scientific reference only. Administration in humans should only occur under qualified medical supervision following thorough informed consent and risk-benefit analysis.
Long-term storage
Max 4 weeks
| Handling Note | Guidance |
|---|---|
| Reconstitution | Inject bac water slowly down vial wall; swirl gently — do not shake |
| Light exposure | Protect from direct sunlight at all times |
| Freeze-thaw cycles | Avoid repeated cycles — reduces peptide integrity |
| Sterility | Maintain aseptic technique throughout handling |
| Labeling | Mark reconstitution date on vial; discard after 4 weeks |
| Purity standard | ≥99% purity, GMP-compliant facility recommended |
Safety Profile & Regulatory Status
Current evidence, known risks, regulatory context, and important considerations for GLOW's component peptides.
● Observed Safety Profile
- No lethal or toxic dose identified in any BPC-157 preclinical safety studies
- BPC-157 IV infusions up to 20mg well-tolerated in healthy adults (Lee & Burgess, 2025)
- TB-500 Phase II trials confirmed safe and well-tolerated in wound healing populations
- GHK-Cu naturally occurring in human plasma; no copper toxicity reported at standard doses
- Common side effects: mild injection site reactions, temporary fatigue, occasional GI discomfort
- No adverse effects reported across >35 BPC-157 preclinical studies reviewed (2025 systematic review)
● Theoretical & Known Risks
- VEGFR2 upregulation by BPC-157: theoretical oncological risk — VEGF/VEGFR2 active in ~50% of human cancers (pharma review, 2023)
- FAK-paxillin activation: these pathways are exploited by aggressive tumors for invasion
- TB-500 angiogenic activity: relative contraindication in active malignancy
- Copper overload: possible with GHK-Cu if co-administering copper-containing supplements
- Human clinical safety data remains limited for BPC-157 and TB-500
- Unknown long-term effects in humans — no trials exceeding weeks in length
● BPC-157 Regulatory Status
- Not FDA-approved for any human therapeutic use
- FDA explicitly flagged BPC-157 as unsafe for compounding (late 2023)
- Previously temporarily banned by WADA (2022); not currently on WADA prohibited list
- Increasingly used by clinicians in cash-pay practices for musculoskeletal indications
- Available as "research chemical" — legal gray area internationally
- Well-designed human RCTs needed before clinical recommendations can be made
● TB-500 & GHK-Cu Status
- TB-500: Not FDA-approved; WADA monitored as potential performance-enhancing agent
- TB-500 has completed Phase II clinical trials for wound healing (venous stasis, pressure ulcers)
- GHK-Cu: Widely available topically as a cosmeceutical ingredient — regulatory-compliant in skin care
- GHK-Cu injectable: not approved, requires medical oversight
- All three peptides are available for legitimate laboratory research use
GLOW Blend — Original Research Data Tables
Component stability, mechanism comparison, and reconstitution reference for laboratory research.
| Healing Phase | GHK-Cu | TB-500 | BPC-157 |
|---|---|---|---|
| Angiogenesis | VEGF modulation (indirect) | VEGF upregulation + endothelial migration | VEGF/VEGFR2 direct upregulation (primary) |
| Cell Migration | Fibroblast chemotaxis | Actin G:F dynamics (primary mechanism) | FAK-paxillin phosphorylation |
| Matrix Synthesis | Collagen I/III/IV, elastin, GAGs (primary) | ILK-mediated ECM interaction | GH receptor → local IGF-1 anabolic signal |
| Anti-Inflammatory | NF-κB suppression | NF-κB suppression + cytokine reduction | NF-κB suppression + NOS modulation |
| Epithelialization | Indirect (matrix support) | Primary driver (keratinocyte migration) | Secondary role |
| Gene Regulation | >4,000 genes modulated (primary) | ILK/Akt/β-catenin pathway genes | GH receptor + NOS genes |
| Antioxidant | SOD/catalase upregulation (direct) | Indirect (inflammation reduction) | NOS modulation → ROS balance |
| Condition | GHK-Cu | TB-500 | BPC-157 |
|---|---|---|---|
| −20°C, sealed, dark | 24–36 mo | 24–36 mo | 24–36 mo |
| 4°C, sealed | 6–12 mo | 6–12 mo | 6–12 mo |
| 25°C (room temp) | 2–4 mo | 3–6 mo | 1–3 mo |
| Light sensitivity | HIGH — amber vial required | Low | Low |
| Reconstituted at 4°C (BW) | 4–6 weeks | 3–4 weeks | 3–4 weeks |
| BW Volume | GHK-Cu Conc. | TB-500 Conc. | BPC-157 Conc. | Per 0.1mL (each) |
|---|---|---|---|---|
| 1.0 mL | 10 mg/mL | 10,000 mcg/mL | 10,000 mcg/mL | 1mg / 1000mcg / 1000mcg |
| 2.0 mL | 5 mg/mL | 5,000 mcg/mL | 5,000 mcg/mL | 0.5mg / 500mcg / 500mcg |
| 5.0 mL | 2 mg/mL | 2,000 mcg/mL | 2,000 mcg/mL | 0.2mg / 200mcg / 200mcg |
| 10.0 mL | 1 mg/mL | 1,000 mcg/mL | 1,000 mcg/mL | 0.1mg / 100mcg / 100mcg |
⚠ GHK-Cu solution should appear pale blue. Colorless indicates Cu²⁺ dissociation — check pH and diluent. TB-500 and BPC-157 solutions should be clear and colorless.
Sourcing the GLOW Blend for Laboratory Research
The multi-peptide composition of the GLOW Blend — GHK-Cu, TB-500, and BPC-157 — demands verified purity and accurate concentration for each component. Researchers can source the research-grade GLOW Blend, independently tested, from Purely Peptides. Their catalog also includes the individual components — GHK-Cu and BPC-157 — for researchers studying individual peptide activity.
All compounds sold strictly for in vitro and laboratory research use only. Not for human administration.
Scientific References
Peer-reviewed publications, systematic reviews, and clinical studies supporting the data presented on this page.
Common Questions About GLOW
Answers to frequently asked questions about the GLOW peptide blend, its components, safety profile, and research status.
What is the GLOW peptide blend?
GLOW is a synergistic triple-peptide formulation combining BPC-157, TB-500 (Thymosin Beta-4 fragment), and GHK-Cu (copper peptide) in a 5:1:1 ratio. Each peptide operates through distinct molecular pathways — nitric oxide signaling, actin cytoskeletal dynamics, and TGFβ1/gene regulation — with converging effects on tissue repair, collagen synthesis, angiogenesis, and cellular regeneration.
What is the 5:1:1 ratio in the GLOW blend?
The 5:1:1 ratio describes the relative proportions of the three peptides: GHK-Cu at 5 parts (71.4%), TB-500 at 1 part (14.3%), and BPC-157 at 1 part (14.3%). In a standard research dose of 2.33 mg total, this equals approximately 1.70 mg GHK-Cu, 0.33 mg TB-500, and 0.33 mg BPC-157. GHK-Cu anchors the blend at the highest dose due to its gene-regulatory and collagen-synthesis activity spanning 4,000+ human genes.
Is the GLOW peptide blend FDA approved?
No. BPC-157, TB-500, and injectable GHK-Cu are not FDA-approved pharmaceutical drugs. BPC-157 was explicitly flagged by the FDA for compounding concerns in late 2023. TB-500 has completed Phase II clinical trials for wound healing. All three are available for legitimate laboratory and research use only. Any human application requires direct supervision by a licensed medical professional.
What does BPC-157 do in the GLOW blend?
BPC-157 (Body Protection Compound, 15 amino acids) provides vascular support and structural reattachment via nitric oxide pathway modulation through the Akt-eNOS axis. It activates VEGFR2 signaling to drive angiogenesis, stimulates FAK-paxillin and ERK1/2 cascades for fibroblast migration, and promotes tendon outgrowth. Over 544 peer-reviewed studies have examined BPC-157 across musculoskeletal, gastrointestinal, and neurological applications.
What does TB-500 do and how does it differ from BPC-157?
TB-500 regulates actin polymerization as the primary G-actin sequestering molecule in mammalian cells, driving cellular migration to injury sites and preventing fibrotic scarring. Unlike BPC-157 which focuses on tendon, GI, and NO pathways, TB-500 excels in cardiac repair, dermal wound healing, and anti-fibrotic applications. It polarizes macrophages to the regenerative M2 phenotype and has completed Phase II clinical trials for venous stasis and pressure ulcers.
Why is GHK-Cu the dominant peptide in GLOW at 5 parts?
GHK-Cu modulates over 4,000 human genes — approximately 31.2% of the entire human genome at a ≥50% change threshold — via the Broad Institute Connectivity Map. It simultaneously stimulates collagen synthesis while regulating its breakdown through MMP/TIMP modulation. Head-to-head clinical data shows it outperforms Vitamin C and retinoic acid for collagen induction. Its broad gene-regulatory activity justifies its dominant position in the 5:1:1 formulation.